Don't Wait, Go Direct

BAFIERTAM, a treatment for relapsing MS, offers lighter GI impact as a non-prodrug monomethyl. HCPs often underestimate symptom severity, relying on habitual prescriptions. Highlighting BAFIERTAM's unique benefits, including  a direct effect without requiring conversion in the GI tract,  was crucial due to slow adoption. In just 3 months, we developed a comprehensive HCP and Patient website advocating for BAFIERTAM as the optimal choice for MS patients. Within 6 months, the client saw a direct effect of our work with an uptick in prescriptions.